Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

1.070 +0.060 (+5.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 289,824
Open 1.030
Bid (Size) 1.030 (60)
Ask (Size) 1.080 (16)
Prev. Close 1.010
Today's Range 1.030 - 1.080
52wk Range 0.8101 - 2.100
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Performance

YTD
-13.7%
-13.7%
1 Month
-31.8%
-31.8%
3 Month
+13.8%
+13.8%
6 Month
-1.8%
-1.8%
1 Year
-18.3%
-18.3%

More News

Read More
What's going on in today's session
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Monday's session: top gainers and losers
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Selected to Present at Israeli BioMed 2025 Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Which stocks have an unusual volume on Tuesday?
Via Chartmill
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
From Enlivex Therapeutics Ltd
Via GlobeNewswire
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis
Via ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Via ACCESSWIRE
Enlivex Adopts Bitcoin Treasury Reserve Strategy
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Enlivex Therapeutics Ltd. - Ordinary Shares publicly traded?
Yes, Enlivex Therapeutics Ltd. - Ordinary Shares is publicly traded.
What exchange does Enlivex Therapeutics Ltd. - Ordinary Shares trade on?
Enlivex Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares?
The ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares is ENLV on the Nasdaq Stock Market
What is the current price of Enlivex Therapeutics Ltd. - Ordinary Shares?
The current price of Enlivex Therapeutics Ltd. - Ordinary Shares is 1.070
When was Enlivex Therapeutics Ltd. - Ordinary Shares last traded?
The last trade of Enlivex Therapeutics Ltd. - Ordinary Shares was at 09/11/25 04:00 PM ET
What is the market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares?
The market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares is 19.59M
How many shares of Enlivex Therapeutics Ltd. - Ordinary Shares are outstanding?
Enlivex Therapeutics Ltd. - Ordinary Shares has 20M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.